Tarsus Pharmaceuticals, Inc.TARSEarnings & Financial Report
Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.
Revenue
$102.7M
Gross Profit
N/A
Operating Profit
$-22.2M
Net Profit
$-20.3M
Gross Margin
N/A
Operating Margin
-21.6%
Net Margin
-19.8%
YoY Growth
151.5%
EPS
$-0.48
Tarsus Pharmaceuticals, Inc. Q2 FY2025 Financial Summary
Tarsus Pharmaceuticals, Inc. reported revenue of $102.7M (up 151.5% YoY) for Q2 FY2025, with a net profit of $-20.3M (up 38.9% YoY) (-19.8% margin).
Key Financial Metrics
| Total Revenue | $102.7M |
|---|---|
| Net Profit | $-20.3M |
| Gross Margin | N/A |
| Operating Margin | -21.6% |
| Report Period | Q2 FY2025 |
Tarsus Pharmaceuticals, Inc. Annual Revenue by Year
Tarsus Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $451.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $451.4M |
| 2024 | $183.0M |
Tarsus Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Tarsus Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $151.7M | +128.4% | $-8.4M | -5.5% |
| Q3 FY2025 | $118.7M | +146.7% | $-12.6M | -10.6% |
| Q2 FY2025 | $102.7M | +151.5% | $-20.3M | -19.8% |
| Q1 FY2025 | $78.3M | +183.7% | $-25.1M | -32.1% |
| Q4 FY2024 | $66.4M | +407.9% | $-23.1M | -34.8% |
| Q3 FY2024 | $48.1M | +2471.8% | $-23.4M | -48.7% |
| Q2 FY2024 | $40.8M | — | $-33.3M | -81.6% |
| Q1 FY2024 | $27.6M | +1004.6% | $-35.7M | -129.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.6M | $40.8M | $48.1M | $66.4M | $78.3M | $102.7M | $118.7M | $151.7M |
| YoY Growth | 1004.6% | N/A | 2471.8% | 407.9% | 183.7% | 151.5% | 146.7% | 128.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $349.3M | $376.8M | $376.3M | $377.0M | $500.8M | $495.0M | $534.6M | $562.2M |
| Liabilities | $74.1M | $124.6M | $138.8M | $152.5M | $158.3M | $162.4M | $199.5M | $218.7M |
| Equity | $275.2M | $252.2M | $237.5M | $224.5M | $342.5M | $332.6M | $335.1M | $343.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.8M | $-14.4M | $-8.7M | $-22.2M | $-20.7M | $-29.4M | $18.3M | $19.3M |